次世代抗体治療薬の世界市場レポート 2025年

次世代抗体治療薬市場規模は、今後数年で急成長が見込まれます。2029年には115億2,000万米ドルに成長し、CAGRは10.9%となります。予測期間の成長は、バイオシミラー開発、二重特異性抗体開発、ナノボディ開発、患者中心のアプローチ、免疫調節抗体、自己免疫疾患への応用拡大、連続製造に起因すると考えられます。予測期間における主な動向としては、抗体工学の進歩、抗体設計におけるデジタル技術、業界との提携、ドラッグデリバリーシステムの進歩、抗体開発における実環境でのエビデンスなどが挙げられます。

予想される慢性疾患の増加は、次世代抗体治療薬市場の成長を促進します。慢性疾患は1年以上続くため、継続的な治療が必要となり、日常生活も制限されることが多いです。次世代抗体治療薬は、慢性疾患患者に的を絞ったケアを提供し、患者の予後改善に貢献するという極めて重要な役割を担っています。2023年1月に米国国立生物工学情報センター（NCBI）が発表した予測によると、少なくとも1つの慢性疾患を持つ50歳以上の高齢者の数は、2050年までに99.5％急増し、1億4,266万人に達すると予想されています。このことは、慢性疾患の蔓延の深刻化に対処する上で、次世代抗体治療薬が極めて重要な役割を果たすことを強調しています。

製薬会社の需要の増加は、次世代抗体治療薬市場の成長を促進します。創薬、市場開拓、生産、マーケティングに重点を置く製薬業界は、ヘルスケアにおいて重要な役割を果たしています。次世代抗体治療薬は、ターゲット精度の向上、副作用の軽減、個別化医療、半減期の延長、投与間隔の革新、多機能抗体、製造プロセスの最適化などの利点を提供します。2023年6月、欧州製薬団体連合会（EFPIA）は、2022年の欧州の医薬品総生産額が3,842億米ドル（3,400億ユーロ）に達し、2021年から4.95％増加したと報告しました。これは、製薬企業に対する需要の高まりを裏付けるものであり、次世代抗体治療薬市場を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界次世代抗体治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の次世代抗体治療薬市場：成長率分析
• 世界の次世代抗体治療薬市場の実績：規模と成長, 2019-2024
• 世界の次世代抗体治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界次世代抗体治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の次世代抗体治療薬市場抗体の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• ポリクローナル抗体
• 生体特異性抗体
• 抗体薬物複合体
• その他のタイプ
• 世界の次世代抗体治療薬市場治療領域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 自己免疫疾患
• 感染症
• 神経変性疾患
• その他の治療領域
• 世界の次世代抗体治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 調査機関
• 製薬およびバイオテクノロジー企業
• その他のエンドユーザー
• 世界の次世代抗体治療薬市場、モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• IgGモノクローナル抗体
• IgMモノクローナル抗体
• 世界の次世代抗体治療薬市場、ポリクローナル抗体のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血清由来ポリクローナル抗体
• ハイブリドーマ由来ポリクローナル抗体
• 世界の次世代抗体治療薬市場、二重特異性抗体のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 二重標的抗体
• 単鎖可変フラグメント（scFv）抗体
• 世界の次世代抗体治療薬市場抗体薬物複合体（ADC）の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ターゲットADC
• ペイロードの種類
• 世界の次世代抗体治療薬市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ナノボディ
• 改変抗体

第7章 地域別・国別分析

• 世界の次世代抗体治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の次世代抗体治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 次世代抗体治療薬市場：競合情勢
• 次世代抗体治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• Moderna Inc.
• BioNTech SE
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Celgene Corporation
• Lonza Group AG
• Catalent Inc.
• Genentech Inc.
• Kyowa Hakko Kirin Co. Ltd.
• Samsung Biologics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 次世代抗体治療薬市場2029：新たな機会を提供する国
• 次世代抗体治療薬市場2029：新たな機会を提供するセグメント
• 次世代抗体治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Next-generation antibody therapeutics represent a class of advanced antibody-based drugs characterized by enhanced structures, functionalities, and therapeutic potential beyond traditional monoclonal antibodies. These therapeutics are employed to address severe medical conditions, including cancer, infectious infections, and immunological disorders.

The main types of antibodies in next-generation antibody therapeutics include monoclonal antibodies, polyclonal antibodies, biospecific antibodies, antibody-drug conjugates, and others. Monoclonal antibodies are laboratory-produced proteins designed to bind to specific targets, such as antigens on the surface of cancer cells. These therapeutics find applications across various therapeutic areas, including oncology, autoimmune diseases, infectious diseases, neurodegenerative disorders, and others. They are utilized in hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, and other relevant entities.

The next-generation antibody therapeutics market research report is one of a series of new reports from The Business Research Company that provides next-generation antibody therapeutics market statistics, including next-generation antibody therapeutics industry global market size, regional shares, competitors with a next-generation antibody therapeutics market share, detailed next-generation antibody therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation antibody therapeutics industry. This next-generation antibody therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The next-generation antibody therapeutics market size has grown rapidly in recent years. It will grow from $6.82 billion in 2024 to $7.63 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to monoclonal antibody success, rising prevalence of chronic diseases, approval of antibody-drug conjugates, growth of immunotherapy, gene therapy and antibodies

The next-generation antibody therapeutics market size is expected to see rapid growth in the next few years. It will grow to $11.52 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to biosimilar development, bispecific antibodies development, nanobody development, patient-centric approaches, immunomodulatory antibodies, expanded applications in autoimmune diseases, continuous manufacturing. Major trends in the forecast period include advancements in antibody engineering, digital technologies in antibody design, industry collaborations, advancements in drug delivery systems, real-world evidence in antibody development.

The anticipated rise in the prevalence of chronic diseases is poised to drive the growth of the next-generation antibody therapeutics market. Chronic diseases, enduring for a year or more, necessitate continuous medical care and often restrict daily activities. Next-generation antibody therapeutics play a pivotal role in offering targeted care for individuals with chronic illnesses, contributing to improved patient outcomes. As per projections from the National Center for Biotechnology Information (NCBI) in January 2023, the number of individuals aged 50 and older with at least one chronic illness is expected to surge by 99.5% by the year 2050, reaching 142.66 million. This underscores the pivotal role of next-generation antibody therapeutics in addressing the escalating prevalence of chronic diseases.

The increasing demand for pharmaceutical companies is set to propel the growth of the next-generation antibody therapeutics market. With a focus on drug discovery, development, production, and marketing, the pharmaceutical industry plays a crucial role in healthcare. Next-generation antibody therapeutics offer advantages such as improved targeting precision, reduced side effects, personalized medicine, extended half-life, dosage interval innovations, multifunctional antibodies, and optimized manufacturing processes. In June 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA) reported that the total pharmaceutical production in Europe reached $384,200 million (€340,000 million) in 2022, marking a 4.95% increase from 2021. This underscores the growing demand for pharmaceutical companies, thereby driving the next-generation antibody therapeutics market.

Technological advancements are a significant trend gaining traction in the next-generation antibody therapeutics market. Major companies in this field are focusing on developing innovations like proprietary Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology to enhance protein identification and characterization, resulting in more targeted and effective treatments. These advancements are intended to improve therapeutic profiles, reduce costs, and tackle complex diseases with greater precision. MIPSA technology organizes protein molecules into structured assemblies for better analysis and quantification, increasing sensitivity and accuracy in protein detection, which is beneficial for research and diagnostics. For example, in January 2024, Infinity Bio, Inc., a US-based biotechnology firm, launched a next-generation antibody profiling platform that employs MIPSA technology for high-throughput, cost-effective analysis of immune responses, with the goal of improving disease understanding and personalizing treatment strategies.

Collaborations and partnerships are strategic trends gaining traction in the next-generation antibody therapeutics market. Such collaborations facilitate innovation, harness complementary expertise, and expedite the development and commercialization of advanced therapies. In December 2023, AbbVie Inc., a US-based pharmaceutical company, collaborated with BigHat Biosciences, a protein therapeutics company, to leverage machine learning (ML) and artificial intelligence (AI) for discovering therapeutic antibodies. This collaboration aims to advance the development of next-generation therapeutic antibodies through BigHat Biosciences' Milliner platform, combining ML technologies with a high-speed wet lab for antibody design and selection.

In October 2022, AbbVie, a US-based pharmaceutical company, acquired DJS Antibodies Ltd., a UK-based developer of therapeutic monoclonal antibodies. This strategic acquisition enhances AbbVie's antibody research initiatives, expands its immunology portfolio, and strengthens its position in Oxford's thriving bioscience sector.

Major companies operating in the next-generation antibody therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Moderna Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Celgene Corporation, Lonza Group AG, Catalent Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics, WuXi Biologics, Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc.

North America was the largest region in the next-generation antibody therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the next-generation antibody therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The next-generation antibody therapeutics market consists of revenues earned by entities by providing services such as antibody engineering, antibody manufacturing, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation antibody therapeutics market also includes sales of immune checkpoint inhibitors, antibody-targeted nanoparticles, and antibody-mimetic proteins. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next-Generation Antibody Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on next-generation antibody therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for next-generation antibody therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The next-generation antibody therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Types Of Antibodies: Monoclonal Antibodies; Polyclonal Antibodies; Biospecific Antibodies; Antibody-Drug Conjugates; Other Types
• 2) By Therapeutic Area: Oncology; Autoimmune Diseases; Infectious Diseases; Neurodegenerative Disorders; Other Therapeutic Areas
• 3) By End-User: Hospitals And Clinics; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End-Users
• Subsegments:
• 1) By Monoclonal Antibodies: IgG Monoclonal Antibodies; IgM Monoclonal Antibodies
• 2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies; Hybridoma-Derived Polyclonal Antibodies
• 3) By Bispecific Antibodies: Dual-Targeting Antibodies; Single-Chain Variable Fragment (scFv) Antibodies
• 4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs; Payload Types
• 5) By Other Types: Nanobodies; Engineered Antibodies
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Bayer AG; Bristol-Myers Squibb Company; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Next-Generation Antibody Therapeutics Market Characteristics

3. Next-Generation Antibody Therapeutics Market Trends And Strategies

4. Next-Generation Antibody Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Next-Generation Antibody Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Next-Generation Antibody Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Next-Generation Antibody Therapeutics Market Growth Rate Analysis
• 5.4. Global Next-Generation Antibody Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Next-Generation Antibody Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Next-Generation Antibody Therapeutics Total Addressable Market (TAM)

6. Next-Generation Antibody Therapeutics Market Segmentation

• 6.1. Global Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Polyclonal Antibodies
• Biospecific Antibodies
• Antibody-Drug Conjugates
• Other Types
• 6.2. Global Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Neurodegenerative Disorders
• Other Therapeutic Areas
• 6.3. Global Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Research Institutes
• Pharmaceutical And Biotechnology Companies
• Other End-Users
• 6.4. Global Next-Generation Antibody Therapeutics Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• IgG Monoclonal Antibodies
• IgM Monoclonal Antibodies
• 6.5. Global Next-Generation Antibody Therapeutics Market, Sub-Segmentation Of Polyclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Serum-Derived Polyclonal Antibodies
• Hybridoma-Derived Polyclonal Antibodies
• 6.6. Global Next-Generation Antibody Therapeutics Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dual-Targeting Antibodies
• Single-Chain Variable Fragment (scFv) Antibodies
• 6.7. Global Next-Generation Antibody Therapeutics Market, Sub-Segmentation Of Antibody-Drug Conjugates (ADCs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted ADCs
• Payload Types
• 6.8. Global Next-Generation Antibody Therapeutics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nanobodies
• Engineered Antibodies

7. Next-Generation Antibody Therapeutics Market Regional And Country Analysis

• 7.1. Global Next-Generation Antibody Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Next-Generation Antibody Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Next-Generation Antibody Therapeutics Market

• 8.1. Asia-Pacific Next-Generation Antibody Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Next-Generation Antibody Therapeutics Market

• 9.1. China Next-Generation Antibody Therapeutics Market Overview
• 9.2. China Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Next-Generation Antibody Therapeutics Market

• 10.1. India Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Next-Generation Antibody Therapeutics Market

• 11.1. Japan Next-Generation Antibody Therapeutics Market Overview
• 11.2. Japan Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Next-Generation Antibody Therapeutics Market

• 12.1. Australia Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Next-Generation Antibody Therapeutics Market

• 13.1. Indonesia Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Next-Generation Antibody Therapeutics Market

• 14.1. South Korea Next-Generation Antibody Therapeutics Market Overview
• 14.2. South Korea Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Next-Generation Antibody Therapeutics Market

• 15.1. Western Europe Next-Generation Antibody Therapeutics Market Overview
• 15.2. Western Europe Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Next-Generation Antibody Therapeutics Market

• 16.1. UK Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Next-Generation Antibody Therapeutics Market

• 17.1. Germany Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Next-Generation Antibody Therapeutics Market

• 18.1. France Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Next-Generation Antibody Therapeutics Market

• 19.1. Italy Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Next-Generation Antibody Therapeutics Market

• 20.1. Spain Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Next-Generation Antibody Therapeutics Market

• 21.1. Eastern Europe Next-Generation Antibody Therapeutics Market Overview
• 21.2. Eastern Europe Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Next-Generation Antibody Therapeutics Market

• 22.1. Russia Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Next-Generation Antibody Therapeutics Market

• 23.1. North America Next-Generation Antibody Therapeutics Market Overview
• 23.2. North America Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Next-Generation Antibody Therapeutics Market

• 24.1. USA Next-Generation Antibody Therapeutics Market Overview
• 24.2. USA Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Next-Generation Antibody Therapeutics Market

• 25.1. Canada Next-Generation Antibody Therapeutics Market Overview
• 25.2. Canada Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Next-Generation Antibody Therapeutics Market

• 26.1. South America Next-Generation Antibody Therapeutics Market Overview
• 26.2. South America Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Next-Generation Antibody Therapeutics Market

• 27.1. Brazil Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Next-Generation Antibody Therapeutics Market

• 28.1. Middle East Next-Generation Antibody Therapeutics Market Overview
• 28.2. Middle East Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Next-Generation Antibody Therapeutics Market

• 29.1. Africa Next-Generation Antibody Therapeutics Market Overview
• 29.2. Africa Next-Generation Antibody Therapeutics Market, Segmentation By Types Of Antibodies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Next-Generation Antibody Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Next-Generation Antibody Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Next-Generation Antibody Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Next-Generation Antibody Therapeutics Market Competitive Landscape
• 30.2. Next-Generation Antibody Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Next-Generation Antibody Therapeutics Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Gilead Sciences Inc.
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Amgen Inc.
• 31.6. Moderna Inc.
• 31.7. BioNTech SE
• 31.8. Regeneron Pharmaceuticals Inc.
• 31.9. Biogen Inc.
• 31.10. Celgene Corporation
• 31.11. Lonza Group AG
• 31.12. Catalent Inc.
• 31.13. Genentech Inc.
• 31.14. Kyowa Hakko Kirin Co. Ltd.
• 31.15. Samsung Biologics

32. Global Next-Generation Antibody Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Next-Generation Antibody Therapeutics Market

34. Recent Developments In The Next-Generation Antibody Therapeutics Market

35. Next-Generation Antibody Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Next-Generation Antibody Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Next-Generation Antibody Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Next-Generation Antibody Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer